Clinical effect of magnesium isoglycyrrhizinate on moderate and severe nonalcoholic steatohepatitis and its mechanism analyse
- VernacularTitle:异甘草酸镁联合降脂治疗中、重度NASH的疗效及机制分析
- Author:
Yuan TIAN
;
Xiaohui TANG
;
Hongyan LI
;
Yong CHENG
;
Yubing WANG
;
Yaning WEI
- Publication Type:Journal Article
- Keywords:
magnesium isoglycyrrhizinate;
simvastatin;
nonalcoholic steatohepatitis;
liver ifbrosis
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):112-114
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of magnesium isoglycyrrhizinate on moderate and severe nonalcoholic steatohepatitis(NASH) and analyse its mechanism. Methods 42 cases with moderate and severe nonalcoholic steatohepatitis were selected in our study. All patients were divided into observation group and control group randomly. Control group were received simvastatin while the observation group were received simvastatin combined with magnesium isoglycyrrhizinate treatment. The course was 6 weeks.The changes of NASH classiifcation, clinical symptom, liver function, lipid levels and liver ifbrosis items in two groups before and after treatment were observed and recorded. Results All patients were received 6 week treatment, none of them dropped out. The clinical symptoms were improved in both two groups. There were 5 severe NASH improved to moderate NASH, 8 moderate NASH improved to mild NASH in observation group while only 3 severe NASH improved to moderate NASH in control group. The difference of NASH classiifcation between two groups was signiifcant(P<0.05). Compared to pre-treatment, the AST, ALT, TBIL,γ-GT were decreased in both two groups. But the liver function items in observation were lower than control group(P<0.05). The lipid level were decreased in both two group and there were no signiifcant differences between two groups after treatment. The level of PC III, HA, C-IV were decreased in observation group while had no changes in control group. Conclusion The magnesium isoglycyrrhizinate could decrease the AST, ALT and lipid level, improve the classiifcation of liver ifbrosis, and had low rate of side effect during treatment.
